UBX Stock Price, UNITY Biotechnology Inc Quote, Chart

Market Summary

USD1.49+0.02

Delayedas of 17 May 2024, 01:02 pm

1.36%

UBX Stock Price

View Fullscreen

UBX RSI Chart

UBX Valuation

Market Cap

24.7M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

108.14

Price/Free Cashflow

-0.8

UBX Price/Sales (Trailing)

UBX Profitability

Return on Equity

-168.29%

Return on Assets

-68.58%

Free Cashflow Yield

-125.47%

UBX Fundamentals

UBX Revenue

Revenue (TTM)

236.0K

UBX Earnings

Earnings (TTM)

-40.4M

Earnings Growth (Yr)

-9.68%

Earnings Growth (Qtr)

-33.36%

Breaking Down UBX Revenue

52 Week Range

1.483.82

(Low)(High)

Last 7 days

-6.9%

Last 30 days

-2.0%

Last 90 days

-23.6%

Trailing 12 Months

-46.2%

How does UBX drawdown profile look like?

UBX Financial Health

Current Ratio

4.98

UBX Investor Care

Shares Dilution (1Y)

16.88%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	3.6M	2.5M	1.4M	236.0K
2021	0	0	0	4.8M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of UNITY Biotechnology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	ghosh anirvan	sold	-934	1.55	-603	chief executive officer
Mar 26, 2024	nguyen alexander hieu	acquired	-	-	20,000	chief legal officer
Feb 02, 2024	ghosh anirvan	sold	-1,162	1.71	-680	chief executive officer
Jan 30, 2024	ghosh anirvan	sold	-2,022	1.71	-1,183	chief executive officer
Nov 02, 2023	ghosh anirvan	sold	-1,077	1.83	-589	chief executive officer
Oct 30, 2023	ghosh anirvan	sold	-1,945	1.9	-1,024	chief executive officer
Sep 14, 2023	ghosh anirvan	sold	-3,077	2.47	-1,246	chief executive officer
Aug 02, 2023	ghosh anirvan	sold	-1,708	2.94	-581	chief executive officer
Jul 31, 2023	ghosh anirvan	sold	-2,917	2.86	-1,020	chief executive officer
Jun 26, 2023	ghosh anirvan	sold	-3,766	3.2	-1,177	chief executive officer

Which funds bought or sold UBX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	102	3,369	8,055	-%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-11.65	-500,948	1,508,820	0.01%
May 15, 2024	Laurion Capital Management LP	sold off	-100	-41,628	-	-%
May 15, 2024	ARCH Venture Management, LLC	unchanged	-	-291,397	1,647,900	2.05%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	180	35,913	61,848	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-24.06	-63,460	115,451	0.01%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-14,500	82,000	-%
May 15, 2024	Royal Bank of Canada	reduced	-69.41	-1,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	92.27	59,544	153,489	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	new	-	29,299	29,299	-%

Are Funds Buying or Selling UBX?

Are funds buying UBX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UBX

No. of Funds

Unveiling UNITY Biotechnology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alyeska investment group, l.p.	9.99%	1,676,818	SC 13G/A
May 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	alyeska investment group, l.p.	9.99%	1,419,000	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Oct 11, 2022	fmr llc	-	0	SC 13G/A
Sep 12, 2022	fmr llc	-	0	SC 13G/A
Feb 14, 2022	venrock associates vii, l.p.	4.6%	2,680,039	SC 13G/A
Feb 11, 2022	arch venture fund vii, l.p.	17.4%	10,048,181	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jul 01, 2021	baillie gifford & co	4.52%	2,479,068	SC 13G/A

Recent SEC filings of UNITY Biotechnology Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 03, 2024	4	Insider Trading
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 15, 2024	S-8	Employee Benefits Plan
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K

Peers (Alternatives to UNITY Biotechnology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

UNITY Biotechnology Inc News

Latest updates

UNITY Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2017Q4
Revenue	-	-	-	-	-	-	236	-	-	-
Operating Expenses	-47.3%	7,679	14,581	11,848	13,039	14,008	12,494	18,267	14,682	-
S&GA Expenses	1.4%	4,407	4,347	5,413	5,280	4,922	4,941	5,806	5,104	-
R&D Expenses	-29.4%	3,272	4,632	6,435	7,759	9,086	7,553	12,461	9,579	-
Interest Expenses	-99.8%	1.00	566	883	990	866	894	808	826	-
Net Income	70.6%	-4,341	-14,782	-15,456	-7,421	-4,997	-13,137	-18,915	-10,693	-
Net Income Margin	7.2%	-168.89*	-181.94*	-140.48*	-188.43*	-34.77*	-23.58*	-17.52*	-12.69*	-
Free Cashflow	-6.3%	-7,575	-7,125	-11,120	-10,403	-12,289	-14,846	-14,972	-5,036	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.4%	59.00	66.00	69.00	101	114	124	136	98.00	112	125	126	136	148	156	175	165	158	151	142	154	161
Current Assets	-17.4%	39.00	47.00	50.00	73.00	86.00	97.00	103	68.00	81.00	91.00	85.00	88.00	102	101	136	124	115	129	126	141	152
Cash Equivalents	-58.0%	8.00	20.00	8.00	19.00	23.00	13.00	23.00	19.00	16.00	33.00	22.00	13.00	27.00	19.00	50.00	41.00	27.00	39.00	38.00	25.00	36.00
Net PPE	-4.5%	5.00	5.00	5.00	7.00	7.00	8.00	8.00	9.00	9.00	10.00	11.00	11.00	12.00	13.00	14.00	14.00	15.00	17.00	5.00	6.00	6.00
Liabilities	-6.5%	35.00	37.00	42.00	60.00	61.00	68.00	75.00	58.00	62.00	65.00	68.00	70.00	68.00	73.00	77.00	52.00	52.00	31.00	27.00	27.00	14.00
Current Liabilities	-1.4%	8.00	8.00	9.00	22.00	22.00	20.00	18.00	16.00	18.00	17.00	13.00	13.00	10.00	14.00	17.00	16.00	15.00	17.00	14.00	15.00	11.00
Long Term Debt	-	-	-	-	4.00	8.00	11.00	13.00	13.00	15.00	18.00	24.00	25.00	25.00	25.00	24.00	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	14.00	13.00	9.00	7.00	7.00	5.00	3.00	1.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	4.00	8.00	11.00	13.00	13.00	15.00	18.00	24.00	25.00	25.00	25.00	24.00	-	-	-	-	-	-
Shareholder's Equity	-15.5%	24.00	28.00	28.00	41.00	53.00	56.00	61.00	40.00	51.00	60.00	58.00	66.00	80.00	83.00	98.00	112	105	121	115	127	147
Retained Earnings	-1.2%	-490	-484	-480	-465	-449	-444	-437	-432	-418	-400	-389	-372	-355	-339	-319	-292	-273	-245	-227	-205	-182
Additional Paid-In Capital	0.3%	514	513	508	506	503	501	498	472	470	460	447	439	435	422	418	405	379	367	343	333	329
Shares Outstanding	0.0%	17.00	17.00	15.00	15.00	14.00	14.00	10.00	7.00	7.00	6.00	6.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	34.00	-	-	-	33.00	-	-	-	202	-	-	-	326	-	-	-	277	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	31.6%	-5,183	-7,575	-7,114	-11,083	-11,316	-10,366	-12,241	-14,835	-14,972	-5,029	-11,531	-13,409	-15,091	-16,733	-17,200	-19,300	-25,100	-15,721	-16,800	-19,304	-20,596
Share Based Compensation	7.9%	1,394	1,292	1,705	2,247	2,175	2,259	2,210	2,250	2,660	2,941	3,086	2,782	2,744	2,700	3,692	4,104	3,317	3,088	3,823	1,944	1,997
Cashflow From Investing	-147.6%	-7,190	15,114	14,249	9,854	21,278	-191	-36,230	17,693	-5,817	9,078	17,152	-979	14,062	-14,575	-6,608	12,309	3,666	-4,472	25,081	7,284	40,060
Cashflow From Financing	-100.0%	-	4,388	-18,377	-2,625	274	167	51,605	138	4,330	6,862	2,900	1,019	10,064	515	32,859	21,508	8,993	20,868	5,407	881	282

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

UBX Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,721	$ 5,760
General and administrative	3,878	4,798
Total operating expenses	7,599	10,558
Loss from operations	(7,599)	(10,558)
Interest income	513	855
Interest expense	0	(1,002)
Gain (loss) on warrant liability	1,376	5,491
Other income (expense), net	(80)	(65)
Net loss	(5,790)	(5,279)
Other comprehensive (loss) gain
Unrealized gain (loss) on marketable debt securities	(14)	101
Comprehensive loss	$ (5,804)	$ (5,178)
Net loss per share, basic	$ (0.34)	$ (0.37)
Net loss per share, diluted	$ (0.34)	$ (0.37)
Weighted-average number of shares used in computing net loss per share, basic	16,785,090	14,312,887
Weighted-average number of shares used in computing net loss per share, diluted	16,785,090	14,312,887

UBX Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 7,430

$ 19,803

^[1]

Short-term marketable securities

28,902

23,398

^[1]

Prepaid expenses and other current assets

2,187

3,404

^[1]

Total current assets

38,519

46,605

^[1]

Property and equipment, net

4,851

5,082

^[1]

Operating lease right-of-use assets

12,441

12,981

^[1]

Long-term marketable securities

1,952

0

^[1]

Long-term restricted cash

896

^[1]

Other long-term assets

204

126

^[1]

Total assets

58,863

65,690

^[1]

Current liabilities:

Accounts payable

1,398

1,380

^[1]

Accrued compensation

1,154

1,841

^[1]

Accrued and other current liabilities

5,180

4,619

^[1]

Total current liabilities

7,732

7,840

^[1]

Operating lease liability, net of current portion

22,606

23,539

^[1]

Warrant liability

4,537

5,913

^[1]

Total liabilities

34,875

37,292

^[1]

Commitments and contingencies (Note 6)

Stockholders’ equity:

Convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding

0

^[1]

Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 16,786,647 and 16,784,969 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

2

^[1]

Additional paid-in capital

514,167

512,773

^[1]

Accumulated other comprehensive loss

(38)

(24)

^[1]

Accumulated deficit

(490,143)

(484,353)

^[1]

Total stockholders’ equity

23,988

28,398

^[1]

Total liabilities and stockholders’ equity

$ 58,863

$ 65,690

^[1]

[1]	The balance sheet as of December 31, 2023 is derived from the audited financial statements as of that date.

About UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

CEO	Dr. Anirvan Ghosh Ph.D.
WEBSITE	https://unitybiotechnology.com
INDUSTRY	Biotechnology
EMPLOYEES	22

UNITY Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for UNITY Biotechnology Inc? What does UBX stand for in stocks?

UBX is the stock ticker symbol of UNITY Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UNITY Biotechnology Inc (UBX)?

As of Thu May 16 2024, market cap of UNITY Biotechnology Inc is 24.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UBX stock?

You can check UBX's fair value in chart for subscribers.

What is the fair value of UBX stock?

You can check UBX's fair value in chart for subscribers. The fair value of UNITY Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UNITY Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UNITY Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether UBX is over valued or under valued. Whether UNITY Biotechnology Inc is cheap or expensive depends on the assumptions which impact UNITY Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UBX.

What is UNITY Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, UBX's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 108.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UBX PE ratio will change depending on the future growth rate expectations of investors.